NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.74 -0.89 (-1.08%) GOLD FUTURES
2,303.50 -54.20 (-2.30%) DOW
37,960.10 -425.99 (-1.11%) Bitcoin GBP
48,063.69 -2,066.72 (-4.12%)
VRTX Jan 2026 260.000 put
| Previous close | 6.50 |
| Open | 6.10 |
| Bid | 5.20 |
| Ask | 11.00 |
| Strike | 260.00 |
| Expiry date | 2026-01-16 |
| Day's range | 6.10 - 6.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 33 |
ZacksVertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ZacksVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
